Tenofovir ( DrugBank: Tenofovir )

6 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	1
13	多発性硬化症／視神経脊髄炎	1
25	進行性多巣性白質脳症	1
93	原発性胆汁性胆管炎	1
265	脂肪萎縮症	5
325	遺伝性自己炎症疾患	1

2. 筋萎縮性側索硬化症

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02437110 (ClinicalTrials.gov)	April 1, 2019	5/5/2015	HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (AL ...	HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (AL ...	Amyotrophic Lateral Sclerosis	Drug: Darunavir;Drug: Ritonavir;Drug: Dolutegravir;Drug: Tenofovir alafenamide (TAF)	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Active, not recruiting	18 Years	N/A	All	122	Phase 1	United States

First Previous1Next Last

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04880577 (ClinicalTrials.gov)	September 15, 2022	30/4/2021	TenofovirAlafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple S ...	TenofovirAlafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple S ...	Multiple Sclerosis, Relapsing-Remitting;Fatigue	Drug: TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY];Drug: Placebo	Massachusetts General Hospital	Gilead Sciences	Withdrawn	18 Years	N/A	All	0	Phase 2	United States

First Previous1Next Last

25. 進行性多巣性白質脳症

臨床試験数 : 26 / 薬物数 : 35 - (DrugBank : 22) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 37

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00120367 (ClinicalTrials.gov)	April 2005	11/7/2005	Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive M ...	Early Intensification of Combination Antiretroviral Therapy Including FUZEON® in the Treatment of Pr ...	Leukoencephalopathy, Progressive Multifocal;HIV Infections	Drug: Enfuvirtide;Drug: Tenofovir-Emtricitabine	French National Agency for Research on AIDS and Viral Hepatitis	Hoffmann-La Roche;Gilead Sciences	Completed	18 Years	N/A	Both	30	Phase 2	France

First Previous1Next Last

93. 原発性胆汁性胆管炎

臨床試験数 : 298 / 薬物数 : 252 - (DrugBank : 59) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 115

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03954327 (ClinicalTrials.gov)	June 29, 2020	7/5/2019	Combination Antiretroviral Therapy (cART) for PBC	Randomized Controlled Trail (RCT) of Emtricitabine, TenofovirDisoproxil and Raltegravir for Patients ...	Primary Biliary Cholangitis	Drug: Emtricitabine (FTC)/TenofovirDisoproxil (TDF);Drug: Raltegravir;Drug: Placebo Oral Capsule [CE ...	University of Alberta	Merck Sharp & Dohme Corp.	Recruiting	18 Years	N/A	All	60	Phase 2	Canada

First Previous1Next Last

265. 脂肪萎縮症

臨床試験数 : 112 / 薬物数 : 155 - (DrugBank : 55) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 97

diseases per page:

Showing 1 to 5 of 5 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04903847 (ClinicalTrials.gov)	February 2, 2021	9/10/2020	Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Ten ...	Changes in Weight After Switch to Dolutegravir/Lamivudine or Doravirine/Tenofovir/Lamivudine Compare ...	Hiv;HIV Infections;HIV Lipodystrophy;Osteoporosis;Renal Insufficiency;Weight Gain;Obesity	Drug: Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO];Drug: Doravirine/Lamivudine/Tenofovi ...	Thomas Benfield	NULL	Recruiting	18 Years	N/A	All	126	Phase 4	Denmark
2	EUCTR2005-004021-26-GB (EUCTR)	06/10/2005	05/09/2005	Longitudinal relationship between lipodystrophy and adipocyte mitochondria DNA in HIV Patients: comp ...	Longitudinal relationship between lipodystrophy and adipocyte mitochondria DNA in HIV Patients: comp ...	HIV	Trade Name: SUSTIVA Product Name: Efavirenz Trade Name: COMBIVIR Product Name: AZT/3TC Trade Name: TRUVA ...	University Hospital Birmingham	NULL	Not Recruiting			Female: yes Male: yes	60	Human pharmacology (Phase 1): Therapeutic exploratory (Phase 2): Therapeutic confirmatory - (Phase 3 ...	United Kingdom
3	NCT00119379 (ClinicalTrials.gov)	April 2005	11/7/2005	Effectiveness of Nucleoside Supplementation or Switch to Tenofovirin Reversing Fat Loss in HIV Infec ...	Reversibility of Mitochondrial Toxicity in HIV Lipoatrophy	HIV Infections;Lipodystrophy;Metabolic Diseases;Nutrition Disorders	Drug: NucleomaxX;Drug: Tenofovir Disoproxil Fumarate	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Completed	18 Years	N/A	All	50	Phase 2	United States
4	NCT00647946 (ClinicalTrials.gov)	February 2003	27/3/2008	Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue	A Phase II, Open-Label, Multicentre, Randomised, Comparator Study of Substitution With Tenofoviror A ...	Lipodystrophy	Drug: tenofovir DF;Drug: abacavir 300mg twice daily	Gilead Sciences	NULL	Completed	18 Years	N/A	Both	100	Phase 2	United Kingdom
5	NCT00192660 (ClinicalTrials.gov)	February 2003	12/9/2005	HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)	Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective, Non-randomised, 48 Week Study o ...	HIV-Associated Lipodystrophy Syndrome;Cardiovascular Disease	Drug: Lamivudine;Drug: Stavudine;Drug: Didanosine;Drug: Zidovudine;Drug: Tenofovir;Drug: Abacavir;Dr ...	Kirby Institute	St Vincent's Hospital, Sydney;National Heart, Lung, and Blood Institute (NHLBI)	Completed	18 Years	N/A	Both	80	Phase 4	Australia

First Previous1Next Last

先頭へ

325. 遺伝性自己炎症疾患

臨床試験数 : 5 / 薬物数 : 11 - (DrugBank : 6) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 35

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03304717 (ClinicalTrials.gov)	December 2023	4/8/2017	Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome	Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome	Aicardi Goutières Syndrome	Drug: Tenofovir (TDF) and Emtricitabine (FTC);Other: Placebo	Children's Hospital of Philadelphia	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);National Hum ...	Not yet recruiting	2 Years	18 Years	All	34	Phase 1/Phase 2	United States

First Previous1Next Last

先頭へ